Photocure gets patents in Europe, Russia for acne therapy

Posted on: Fri, 27 Nov 2009 11:08:00 EST


Symbols: PHCUF
Dublin, Nov 27, 2009 (M2 PRESSWIRE via COMTEX) --
PHCUF | Quote | Chart | News | PowerRating -- 27 November 2009 - Norwegian pharmaceutical company Photocure ASA (OSL:
PHO) said Thursday afternoon that the European Patent Office and the
Patent Office in Russia granted a patent on its application, tagged
"PDT Acne".

The awarded patents will provide protection for the use of the
5-ALA-ester methyl aminolevulinate -- MAL being the active ingredient
in Photocure's lead dermatology product Visonac -- and other
5-ALA-esters in the treatment of acne until November 2025.

Visonac is a photodynamic therapy (PDT) combining the Visonac cream
with illumination by a red light source to treat acne. The procedure
kills bacteria and appears to have a beneficial effect on sebaceous
glands and inflammatory cells.

Comments on this story may be sent to 
nbr.feedback@nordicbusinessreport.com

For full details on (PHCUF) PHCUF. (PHCUF) has Short Term PowerRatings at TradingMarkets. Details on (PHCUF) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.